Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model.

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY

British journal of clinical pharmacology Pub Date : 2025-04-27 DOI:10.1002/bcp.70073

Christian Seebauer, Fares Hanafieh, Jan Wolff, Hans-Robert Metelmann, Marcus Vollmer

{"title":"Influence of anticoagulant concomitant medication on wound healing: Analysis of a multicentre cohort of 212 patients with a uniform wound model.","authors":"Christian Seebauer, Fares Hanafieh, Jan Wolff, Hans-Robert Metelmann, Marcus Vollmer","doi":"10.1002/bcp.70073","DOIUrl":null,"url":null,"abstract":"Aims: Various factors can impair wound healing by disrupting key stages of the process. This study evaluates the impact of concomitant anticoagulant medication on wound healing in a cohort of 212 patients.Methods: Data from 2 open-label, blindly evaluated, prospective, randomized, multicentre phase III trials (n = 212) were analysed. Healing durations of patients taking anticoagulants were compared to a control group (split-thickness skin graft donor site halves treated with standard moist wound dressing). Kaplan-Meier estimators and multivariable Cox regression were applied.Results: Kaplan-Meier analysis demonstrated significantly accelerated wound healing in patients treated with enoxaparin or nadroparin. Among monotherapies, 75% of patients on enoxaparin achieved wound closure within 16.5 days (95% confidence interval [CI]: 14-21), and those on nadroparin within 15 days (95% CI: 11.5-19), compared to 24 days (95% CI: 20-28) in patients receiving other anticoagulants (log-rank test: P < .001). Cox regression confirmed a significantly faster healing rate with enoxaparin or nadroparin (hazard ratio = 1.50, 95% CI: 1.02-2.19, P = .039).Conclusion: Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible.","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Various factors can impair wound healing by disrupting key stages of the process. This study evaluates the impact of concomitant anticoagulant medication on wound healing in a cohort of 212 patients.

Methods: Data from 2 open-label, blindly evaluated, prospective, randomized, multicentre phase III trials (n = 212) were analysed. Healing durations of patients taking anticoagulants were compared to a control group (split-thickness skin graft donor site halves treated with standard moist wound dressing). Kaplan-Meier estimators and multivariable Cox regression were applied.

Results: Kaplan-Meier analysis demonstrated significantly accelerated wound healing in patients treated with enoxaparin or nadroparin. Among monotherapies, 75% of patients on enoxaparin achieved wound closure within 16.5 days (95% confidence interval [CI]: 14-21), and those on nadroparin within 15 days (95% CI: 11.5-19), compared to 24 days (95% CI: 20-28) in patients receiving other anticoagulants (log-rank test: P < .001). Cox regression confirmed a significantly faster healing rate with enoxaparin or nadroparin (hazard ratio = 1.50, 95% CI: 1.02-2.19, P = .039).

Conclusion: Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. Anticoagulant monotherapy with enoxaparin or nadroparin should be considered postoperatively when feasible.

查看原文本刊更多论文

抗凝剂联合用药对伤口愈合的影响：一项212例统一伤口模型患者的多中心队列分析

目的：各种因素可以通过破坏伤口愈合过程的关键阶段来损害伤口愈合。本研究评估了在212例患者中同时使用抗凝药物对伤口愈合的影响。方法：对2项开放标签、盲评价、前瞻性、随机、多中心III期试验（n = 212）的数据进行分析。使用抗凝剂的患者的愈合时间与对照组（用标准湿性伤口敷料处理一半的裂厚皮肤移植供体）进行比较。应用Kaplan-Meier估计和多变量Cox回归。结果：Kaplan-Meier分析显示，接受依诺肝素或钠黄素治疗的患者伤口愈合明显加快。在单药治疗中，75%使用依诺肝素的患者在16.5天内（95%可信区间[CI]: 14-21）伤口愈合，使用nadroparin的患者在15天内（95% CI: 11.5-19）伤口愈合，而使用其他抗凝药物的患者在24天内（95% CI: 20-28）伤口愈合（log-rank检验：P）。依诺肝素和nadroparin可促进伤口愈合，而phenprocoumon、乙酰水杨酸和某些低分子量肝素（certoparin、tinzaparin、dalteparin、bemiparin）似乎可延迟伤口愈合。术后可行时应考虑用依诺肝素或钠红素进行单药抗凝治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British journal of clinical pharmacology 医学-药学

CiteScore

6.30

自引率

8.80%

发文量

419

审稿时长

1 months

期刊介绍： Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.